Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.
-
Pasithea's PAS-004 Phase 1 trial advances to 22mg dose with no DLTs or rash, reinforcing its safety profile as a next-gen MEK inhibitor for NF1 and cancer.
-
Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.
-
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
-
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004
-
- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data...